From the pharmaceutical industry, to biotechnology and the production of medical devices and health services, the supply chain of life sciences in Italy the 10% of national GDP is worth and represents a key sector to respond to the challenges of the future, a process accelerated by the Covid-19 pandemic. From the report "100 Italian Life Sciences Stories " from Symbola Foundation and Enel in collaboration with Farmindustria Italy, it appears that Italy is among the first places in Europe together with Germany in pharmaceutical production with the increase in exports in the last 10 years higher among the big Europeans (+ 168% compared to the + 86% of the EU average).
"The companies that work in this field do it for the good of man in an absolute way - said Francesco Starace, CEO and CEO of Enel - and therefore it is extremely interesting to see how Italy expresses excellence precisely when man is the center of attention of the company ".
The pandemic it has led to rethinking many aspects of life starting from attention to health. This is why Symbola and Enel have decided to tell 100 stories of companies, researchers, scientists, universities, start-ups and healthcare structures that "work every day to ensure people's health and make it possible to have the best tools for care and improvement of the quality of life of patients. The report highlights a real excellence for our country, a wealth of skills, innovations and technologies appreciated and recognized all over the world ”, added Starace.
Italy ranks fourth in the world for the number of scientific publications on Covid-19 and Mirandola, in the province of Modena, is the most important biomedical district in Europe and third in the world, after those of Minneapolis and Los Angeles in the United States. United States of America.
For Ermete Realacci, president of the Symbola Foundation, it is necessary to start from excellence to look to the future. "Guaranteeing a vaccine for everyone, defending everyone's health and not leaving anyone behind - he said - Italy has a lot to say in this challenge that requires the contribution of the best technological, institutional, social and cultural energies". "The 100 stories told in the dossier - he added - testify to the quality of business and research institutions that must increasingly be put at the service of a strengthening of local medicine".